The evolution of Taiwan’s National Health Insurance drug reimbursement scheme

[1] Hogerzeil H(2003)Access to essential medicines as a human right World Health Organisation: Essential Drugs Monitor ᅟ 25-26

[2] Gil-Gonzalez D(2014)Is health a right for all? An umbrella review of the barriers to health care access faced by migrants Ethn Health 13 1-19

[3] Carrasco-Portino M(2001)The impact of pipeline drugs on drug spending growth Health Aff (Millwood) 20 210-215

[4] Vives-Cases C(2002)Pharmaceuticals in U.S. health care: determinants of quantity and price J Econ Perspect 16 45-66

[5] Agudelo-Suarez AA(2004)Health spending rebound continues in 2002 Health Aff (Millwood) 23 147-159

[6] Castejon Bolea R(2008)Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective? Value Health 11 334-344

[7] Ronda-Perez E(2014)Ensuring the sustainability of the Taiwan National Health Insurance J Formos Med Assoc 113 1-2

[8] Mullins CD(2005)Economic analysis of NHI pharmaceutical policies and drug expenditures Socioecon Law Inst Rev 35 1-42

[9] Wang J(2009)The future of health technology assessment in healthcare decision making in Asia Pharmacoeconomics 27 891-901

[10] Palumbo FB(2008)The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs BMC Public Health 8 118-205

[1] Hogerzeil H(2003)Access to essential medicines as a human right World Health Organisation: Essential Drugs Monitor ᅟ 25-26

[2] Gil-Gonzalez D(2014)Is health a right for all? An umbrella review of the barriers to health care access faced by migrants Ethn Health 13 1-19

[3] Carrasco-Portino M(2001)The impact of pipeline drugs on drug spending growth Health Aff (Millwood) 20 210-215

[4] Vives-Cases C(2002)Pharmaceuticals in U.S. health care: determinants of quantity and price J Econ Perspect 16 45-66

[5] Agudelo-Suarez AA(2004)Health spending rebound continues in 2002 Health Aff (Millwood) 23 147-159

[6] Castejon Bolea R(2008)Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective? Value Health 11 334-344

[7] Ronda-Perez E(2014)Ensuring the sustainability of the Taiwan National Health Insurance J Formos Med Assoc 113 1-2

[8] Mullins CD(2005)Economic analysis of NHI pharmaceutical policies and drug expenditures Socioecon Law Inst Rev 35 1-42

[9] Wang J(2009)The future of health technology assessment in healthcare decision making in Asia Pharmacoeconomics 27 891-901

[10] Palumbo FB(2008)The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs BMC Public Health 8 118-205